Bis-benzylidine piperidone proteasome inhibitor with anticancer activity
We describe a bis-benzylidine piperidone, RA190, which covalently binds to the ubiquitin receptor RPN13 (ADRM1) in the 19S regulatory particle and inhibits proteasome function, triggering rapid accumulation of polyubiquitinated proteins. Multiple myeloma lines, even those resistant to bortezomib, were sensitive to RA190 via ER stress-related apoptosis. RA190 stabilized targets of human papillomavirus (HPV) E6 oncoprotein, and preferentially killed HPV-transformed cells. After p.o. or i.p. dosing of mice, RA190 distributed to plasma and major organs excepting brain, and potently inhibited proteasome function in skin and muscle. RA190 administration i.p. profoundly reduced growth of multiple myeloma and ovarian cancer xenografts, and oral RA190 treatment retarded HPV+ syngeneic mouse tumor growth, without impacting spontaneous HPV-specific CD8+ T cell responses, suggesting its therapeutic potential. The bis-benzylidine piperidone RA190 is a new orally-available proteasome inhibitor. Multiple myeloma, cervical and ovarian cancers are particularly sensitive to RA190.
1. A method of inhibiting proteasomes in a mammal by administering to the mammal an effective amount of a compound of formula I,
wherein each pair of As is one of:
(i) phenyl, optionally substituted with 1-5 substituents selected from the group consisting of R1, OR1, NR1R2, S(O) q A1, SO 2 NR1R2, NR1SO 2 R2, C(O)R1, C(O)OR1, C(O)NR1R2, NR1C(O)R2, NR1C(O)OR2, CF 3 , and OCF 3 ;
(ii) naphthyl, optionally substituted with 1-5 substituents selected from the consisting of R1, OR1, NR1R2, S(O) q A1, SO 2 NR1R2, NR1SO 2 R2, C(O)R1, C(O)OR1, C(O)NR1R2, NR1C(O)R2, NR1C(O)OR2, CF 3 , and OCF 3 ;
(iii) a 5 or 6 membered monocyclic heteroaryl group, having 1-3 heteroatoms selected from the group consisting of O, N, and S, optionally substituted with 1-3 substituents selected from the group consisting of R1, OR1, NR1R2, S(O) q A1, SO 2 NR1R2, NR1SO 2 R2, C(O)R1, C(O)OR1, C(O)NR1R2, NR1C(O)R2, NR1C(O)OR2, CF 3 , and OCF 3 ; and
(iv) an 8 to 10 membered bicyclic heteroaaryl group containing 1-3 heteroatoms selected from the group consisting of O, N, and S; and the second ring is fused to the first ring using 3 to 4 carbon atoms, and the bicyclic hetero aryl group is optionally substituted with 1-3 substituents selected from the group consisting of R1, OR1, NR1R2, S(O) q A1, SO 2 NR1R2, NR1SO 2 R2, C(O)R1, C(O)OR1, C(O)NR1R2, NR1C(O)R2, NR1C(O)OR2, CF 3 , and OCF 3 ;
wherein X is OR1 or NP, wherein P is selected from the group consisting of R1, C(O)R1, C(O)OR1, C(O)NR1R2, S—N(R1)COOR1, and S—N(R1),
wherein Y is selected from the group consisting of O, S, NR1 and CR1R2,
wherein R1 and R2 are selected from the group consisting of hydrogen, nitro; hydroxyl; carboxy; amino; halogen; cyano; and C 1 -C 14 linear or branched alkyl groups, that are optionally substituted with 1-3 substituents selected from the group consisting of C 1 -C 14 linear or branched alkyl, up to perhalo substituted C 1 -C 14 linear or branched alkyl, C 1 -C 14 alkoxy, hydrogen, nitro, hydroxyl, carboxy, amino, C 1 -C 14 alkylamino, C 1 -C 14 dialkylamino, halogen, and cyano; and
wherein Z is selected from the group consisting of hydrogen; C 1 to C 14 linear, branched, or cyclic alkyls; phenyl; benzyl; 1-5 substituted benzyl; C 1 to C 3 alkyl-phenyl, wherein the alkyl moiety is optionally substituted with halogen up to perhalo; up to perhalo substituted C 1 to C 14 linear or branched alkyls; and —(CH 2 ) q —K, where K is a 5 or 6 membered monocyclic heterocyclic ring, containing 1 to 4 atoms selected from oxygen, nitrogen and sulfur, which is saturated, partially saturated, or aromatic, or an 8 to 10 membered bicyclic heteroaryl having 1-4 heteroatoms selected from the group consisting of O, N and S, wherein said alkyl moiety is optionally substituted with halogen up to perhalo; and wherein the variable q is an integer ranging from 0 to 4; and
wherein inhibiting the proteasomes comprises inhibiting a ubiquitin proteasome system.
2. The method of claim 1 , wherein the mammal is a human.
3. The method of claim 1 , wherein the method treats a condition or a disease in the mammal.
4. The method of claim 3 , wherein the mammal is a human.
5. The method of claim 3 , wherein the condition or disease is a type of cancer.
6. The method of claim 5 , wherein the type of cancer is selected from the group consisting of breast cancer, cervical cancer, ovarian cancer, multiple myeloma, breast cancer and pancreatic cancer.
7. The method of claim 5 , wherein the type of cancer is associated with Human Papilloma Virus (HPV).
8. The method of claim 1 , wherein the compound is administered in combination with at least one other therapeutic agent.
9. The method of claim 8 , wherein the at least one other therapeutic agent is a proteasome inhibitor.
10. The method of claim 8 , wherein the at least one other therapeutic agent is bortezomib.
11. The method of claim 1 , wherein the compound binds to RPN13.
12. The method of claim 1 , wherein the compound is orally administered.
13. The method of claim 1 , wherein the compound is intraperitoneally administered.
14. The method compound of claim 1 , wherein the compound is topically applied.
15. The method of claim 1 , wherein the compound has the structure:
16. A method of inhibiting proteasomes in a mammal by administering to the mammal an effective amount of a compound having the structure:
17. The method of claim 1 , wherein the compound has the structure: